Published in AIDS Weekly, November 20th, 1995
The study (ACTG 251), sponsored through NIAID's AIDS Clinical Trials Group, compares the effectiveness and safety of thalidomide with placebo for treating patients with severe oral and esophageal ulcers. In the second or maintenance phase of the study, doctors are evaluating thalidomide's ability to prevent recurrences of ulcers in the mouth or the esophagus.
As a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1995-11-20)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.